Patents by Inventor Sheila Oren

Sheila Oren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for reducing symptoms of Parkinson's disease
    Patent number: 12161612
    Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
    Type: Grant
    Filed: April 15, 2024
    Date of Patent: December 10, 2024
    Assignee: NeuroDerm, Ltd.
    Inventors: Liat Adar, Nelson Felix Lopes, Laurence Salin, Tamar Yardeni, Nissim Sasson, Sheila Oren, Hikari Yarita, Mikio Himizu, Natalia Vostokova
  • METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE
    Publication number: 20240342124
    Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
    Type: Application
    Filed: April 15, 2024
    Publication date: October 17, 2024
    Inventors: Liat Adar, Nelson Felix Lopes, Laurence Salin, Tamar Yardeni, Nissim Sasson, Sheila Oren, Hikari Yarita, Mikio Himizu, Natalia Vostokova
  • RASAGILINE FOR PARKINSON'S DISEASE MODIFICATION
    Publication number: 20140243418
    Abstract: A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.
    Type: Application
    Filed: November 27, 2013
    Publication date: August 28, 2014
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ruth Levy, Eli Eyal, Tamar Goren, Sheila Oren, Naim Sayag, Yonatan Weiss, Miri Ben-Ami
  • Rasagiline for parkinson's disease modification
    Publication number: 20090312436
    Abstract: A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Inventors: Ruth Levy, Eli Eyal, Tamar Goren, Sheila Oren, Naim Sayag, Yonatan Weiss, Miri Ben-Ami